11 research outputs found
Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells
Acute myeloid leukemia is a malignant disease of immature myeloid cells. Despite significant therapeutic effects of differentiation-inducing agents in some acute myeloid leukemia subtypes, the disease remains incurable in a large fraction of patients. Here we show that SK053, a thioredoxin inhibitor, induces differentiation and cell death of acute myeloid leukemia cells. Considering that thioredoxin knock-down with short hairpin RNA failed to exert antiproliferative effects in one of the acute myeloid leukemia cell lines, we used a biotin affinity probe-labeling approach to identify potential molecular targets for the effects of SK053. Mass spectrometry of proteins precipitated from acute myeloid leukemia cells incubated with biotinylated SK053 used as a bait revealed protein disulfide isomerase as a potential binding partner for the compound. Biochemical, enzymatic and functional assays using fluorescence lifetime imaging confirmed that SK053 binds to and inhibits the activity of protein disulfide isomerase. Protein disulfide isomerase knockdown with short hairpin RNA was associated with inhibition of cell growth, increased CCAAT enhancer-binding protein α levels, and induction of differentiation of HL-60 cells. Molecular dynamics simulation followed by the covalent docking indicated that SK053 binds to the fourth thioredoxin-like domain of protein disulfide isomerase. Differentiation of myeloid precursor cells requires the activity of CCAAT enhancer-binding protein α, the function of which is impaired in acute myeloid leukemia cells through various mechanisms, including translational block by protein disulfide isomerase. SK053 increased the levels of CCAAT enhancer-binding protein α and upregulated mRNA levels for differentiation-associated genes. Finally, SK053 decreased the survival of blasts and increased the percentage of cells expressing the maturation-associated CD11b marker in primary cells isolated from bone marrow or peripheral blood of patients with acute myeloid leukemia. Collectively, these results provide a proof-of-concept that protein disulfide isomerase inhibition has potential as a therapeutic strategy for the treatment of acute myeloid leukemia and for the development of small-molecule inhibitors of protein disulfide isomerase
C16orf57, a gene mutated in poikiloderma with neutropenia, encodes a putative phosphodiesterase responsible for the U6 snRNA 3′ end modification.
C16orf57 encodes a human protein of unknown function, and mutations in the gene occur in poikiloderma with neutropenia (PN), which is a rare, autosomal recessive disease. Interestingly, mutations in C16orf57 were also observed among patients diagnosed with Rothmund-Thomson syndrome (RTS) and dyskeratosis congenita (DC), which are caused by mutations in genes involved in DNA repair and telomere maintenance. A genetic screen in Saccharomyces cerevisiae revealed that the yeast ortholog of C16orf57, USB1 (YLR132C), is essential for U6 small nuclear RNA (snRNA) biogenesis and cell viability. Usb1 depletion destabilized U6 snRNA, leading to splicing defects and cell growth defects, which was suppressed by the presence of multiple copies of the U6 snRNA gene SNR6. Moreover, Usb1 is essential for the generation of a unique feature of U6 snRNA; namely, the 3'-terminal phosphate. RNAi experiments in human cells followed by biochemical and functional analyses confirmed that, similar to yeast, C16orf57 encodes a protein involved in the 2',3'-cyclic phosphate formation at the 3' end of U6 snRNA. Advanced bioinformatics predicted that C16orf57 encodes a phosphodiesterase whose putative catalytic activity is essential for its function in vivo. Our results predict an unexpected molecular basis for PN, DC, and RTS and provide insight into U6 snRNA 3' end formation
3DFlu: database of sequence and structural variability of the influenza hemagglutinin at population scale
Binding Activity Prediction of Cyclin-Dependent Inhibitors
The
Cyclin-Dependent Kinases (CDKs) are the core components coordinating
eukaryotic cell division cycle. Generally the crystal structure of
CDKs provides information on possible molecular mechanisms of ligand
binding. However, reliable and robust estimation of ligand binding
activity has been a challenging task in drug design. In this regard,
various machine learning techniques, such as Support Vector Machine,
Naive Bayesian classifier, Decision Tree, and <i>K</i>-Nearest
Neighbor classifier, have been used. The performance of these heterogeneous
classification techniques depends on proper selection of features
from the data set. This fact motivated us to propose an integrated
classification technique using Genetic Algorithm (GA), Rotational
Feature Selection (RFS) scheme, and Ensemble of Machine Learning methods,
named as the Genetic Algorithm integrated Rotational Ensemble based
classification technique, for the prediction of ligand binding activity
of CDKs. This technique can automatically find the important features
and the ensemble size. For this purpose, GA encodes the features and
ensemble size in a chromosome as a binary string. Such encoded features
are then used to create diverse sets of training points using RFS
in order to train the machine learning method multiple times. The
RFS scheme works on Principal Component Analysis (PCA) to preserve
the variability information of the rotational nonoverlapping subsets
of original data. Thereafter, the testing points are fed to the different
instances of trained machine learning method in order to produce the
ensemble result. Here accuracy is computed as a final result after
10-fold cross validation, which also used as an objective function for
GA to maximize. The effectiveness of the proposed classification technique
has been demonstrated quantitatively and visually in comparison with
different machine learning methods for 16 ligand binding CDK docking
and rescoring data sets. In addition, the best possible features have
been reported for CDK docking and rescoring data sets separately.
Finally, the Friedman test has been conducted to judge the statistical
significance of the results produced by the proposed technique. The results indicate that
the integrated classification technique has high relevance in predicting
of protein–ligand binding activity
Novel combination therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T cell infiltration and modulation of tumor microenvironment in mesothelioma mouse model
IntroductionMalignant mesothelioma is a rare and aggressive form of cancer. Despite improvements in cancer treatment, there are still no curative treatment modalities for advanced stage of the malignancy. The aim of this study was to evaluate the anti-tumor efficacy of a novel combinatorial therapy combining AdV5/3-D24-ICOSL-CD40L, an oncolytic vector, with an anti-PD-1 monoclonal antibody.MethodsThe efficacy of the vector was confirmed in vitro in three mesothelioma cell lines - H226, Mero-82, and MSTO-211H, and subsequently the antineoplastic properties in combination with anti-PD-1 was evaluated in xenograft H226 mesothelioma BALB/c and humanized NSG mouse models.Results and discussionAnticancer efficacy was attributed to reduced tumour volume and increased infiltration of tumour infiltrating lymphocytes, including activated cytotoxic T-cells (GrB+CD8+). Additionally, a correlation between tumour volume and activated CD8+ tumour infiltrating lymphocytes was observed. These findings were confirmed by transcriptomic analysis carried out on resected human tumour tissue, which also revealed upregulation of CD83 and CRTAM, as well as several chemokines (CXCL3, CXCL9, CXCL11) in the tumour microenvironment. Furthermore, according to observations, the combinatorial therapy had the strongest effect on reducing mesothelin and MUC16 levels. Gene set enrichment analysis suggested that the combinatorial therapy induced changes to the expression of genes belonging to the "adaptive immune response" gene ontology category. Combinatorial therapy with oncolytic adenovirus with checkpoint inhibitors may improve anticancer efficacy and survival by targeted cancer cell destruction and triggering of immunogenic cell death. Obtained results support further assessment of the AdV5/3-D24-ICOSL-CD40L in combination with checkpoint inhibitors as a novel therapeutic perspective for mesothelioma treatment.Peer reviewe
MOESM1 of Novel neuro-audiological findings and further evidence for TWNK involvement in Perrault syndrome
Additional file 1: Figure S1. Sequence-to-structure alignment between the human Twinkle protein (Hs) and the template (PDB code 1e0j). The numbers of residues that are not shown are specified in parentheses. Identical residues are highlighted in yellow. Locations of observed (for 1e0j) and predicted (for Hs) secondary structure elements are marked above and below the corresponding sequences. Helices are presented as blue cylinders, while beta strands as orange arrows